Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas), for metastatic castrate-resistant disease has driven considerable growth in the size of the prostate cancer market. Penetration of Zytiga and Xtandi (and other novel hormonal agents) in other patient populations (e.g., biochemical recurrent, non-metastatic castrate-resistant disease) will be major market drivers. Other therapies, including Xofigo (Bayer HealthCare) and Jevtana (Sanofi) offer non-hormonal treatment options. However, optimal sequencing of therapies in the crowded castrate resistant prostate cancer armamentarium is still under reconnaissance.
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Primary research: Survey of 250 European oncologists and urologists (~50 in each of the EU5 countries) fielded in February 2017.
Key companies: Johnson & Johnson, Astellas Pharma (Medivation), Bayer Healthcare, Sanofi-Aventis
Key drugs: Xtandi, Xofigo, Jevtana, Zytiga